Palvella Therapeutics (PVLA) executive compensation, 2026 proxy

Wesley H. Kaupinen, President and Chief Executive Officer, was paid $3.4M in 2025, down 37% from $5.4M the year before.

Filed
April 30, 2026
Annual meeting
June 10, 2026
Pay year
2025
Named executives
3
CEO total pay
$3.4M-37% vs prior year
Prior say-on-pay support
99%of votes cast
CEO Base Salary
$575,000For fiscal year 2025
CEO Target Bonus
50%Percentage of base salary
Corporate Performance Score
100%Achievement level for 2025

How Kaupinen was paid

$3.4M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.

Salary17%Option awards73%Non-equity incentive11%All other compensation0%

Named executive officers

ExecutiveTotal
Wesley H. KaupinenPresident and Chief Executive Officer$3,404,904
Kathleen GoinChief Operating Officer$1,979,837
Matthew E. KorenbergChief Financial Officer$1,971,437

What changed and why

  • $3.4MCEO total compensation decreased to $3,404,904 in fiscal 2025 compared to the prior year.
  • $2.5MStock option awards for the CEO totaled $2,469,886 during the fiscal year.
  • 100%Annual cash bonuses were paid based on a corporate performance score of 100%.
  • 99.1%Say-on-pay received approximately 99.1% support at the prior annual meeting.

About this page

Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.